Recovery research fieldbook Evidence, not treatment advice
Recovery archive

Published recovery field note

Effect of human chorionic gonadotropin on growth velocity

. 1989 Jan;148(4):300-3. doi: 10.1007/BF00444118. Affiliations PMID: 2495961 DOI: 10.1007/BF00444118 Effect of human chorionic gonadotropin on growth velocity and biological growth parameters in adolescents with thalassaemia major M Bozzola et al. Eur J Pediatr. 1989 Jan. Abstract The effect of long-term human chorionic gonadotropin (HCG) therapy on the linear growth and biological growth parameters was studied in six thalassaemic boys aged 14.5-15.5 years old with hypogonadotropic hypogonadism. A significant (P less than 0.001) increase in growth velocity (from 3.3 +/- 0.3 to 7.6 +/- 0.6 cm/year) was found after 6-12 months of therapy, without acceleration of bone age. A striking improvement in pubertal development was observed. The treatment significantly increased growth hormone (GH) response to L-dopa administration (P less than 0.025) as well as sleep GH secretion (P less than 0.025). Serum growth factors, evaluated as thymidine activity during deep sleep, increased (P less than 0

Context first

Study findings do not automatically establish clinical benefit, safety, dosing, or suitability for an individual.

. 1989 Jan;148(4):300-3.

doi: 10.1007/BF00444118.

Affiliations

PMID: 2495961 DOI: 10.1007/BF00444118

Effect of human chorionic gonadotropin on growth velocity and biological growth parameters in adolescents with thalassaemia major

M Bozzola et al. Eur J Pediatr. 1989 Jan.

Abstract

The effect of long-term human chorionic gonadotropin (HCG) therapy on the linear growth and biological growth parameters was studied in six thalassaemic boys aged 14.5-15.5 years old with hypogonadotropic hypogonadism. A significant (P less than 0.001) increase in growth velocity (from 3.3 +/- 0.3 to 7.6 +/- 0.6 cm/year) was found after 6-12 months of therapy, without acceleration of bone age. A striking improvement in pubertal development was observed. The treatment significantly increased growth hormone (GH) response to L-dopa administration (P less than 0.025) as well as sleep GH secretion (P less than 0.025). Serum growth factors, evaluated as thymidine activity during deep sleep, increased (P less than 0.001), but somatomedin C (Sm-C) levels did not. Prior to treatment, baseline and peak values of plasma growth hormone releasing hormone (GH-RH) following L-dopa were low. After HCG therapy, GH-RH response to L-dopa increased significantly (from 9.2 +/- 5.6 to 20.2 +/- 6.2 pg/ml; P less than 0.05), but remained (P less than 0.001) lower than in normal prepubertal children. This study suggests that in thalassaemia major an impaired GH-RH release can be observed, in addition to the described alteration in Sm-C generation.

PubMed Disclaimer

References

Arch Dis Child. 1977 Jun;52(6):489-500 - PubMed

Arch Dis Child. 1976 Nov;51(11):828-36 - PubMed

Pediatrics. 1972 Jul;50(1):92-9 - PubMed

J Clin Endocrinol Metab. 1986 Mar;62(3):466-73 - PubMed

J Clin Endocrinol Metab. 1985 Jun;60(6):1132-4 - PubMed

Connected topics

Follow this recovery question